

# Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis

MARIE HUDSON, MICHAEL MAHLER, JANET POPE, DANIEL YOU, SOLENE TATIBOUET, RUSSELL STEELE, MURRAY BARON, Canadian Scleroderma Research Group, and MARVIN FRITZLER

**ABSTRACT. Objective.** To study the clinical phenotypes of centromeric proteins (CENP)-A- and CENP-B-positive patients with systemic sclerosis (SSc) and to compare them to anticentromere antibody (ACA)-positive and negative SSc patients.

**Methods.** Sera samples were collected from 802 patients with SSc enrolled in a multicenter cohort study. Antibodies to CENP-A and B were detected by ELISA, and ACA by indirect immunofluorescence. Associations with clinical and other serological manifestations of SSc were investigated.

**Results.** CENP-A antibodies were detected in 276 (34%), CENP-B in 286 (36%), and ACA in 279 (35%) patients. Patients having ACA, CENP-A, and/or CENP-B resembled each other and differed from the remainder of the cohort in the following respects: older chronologically and at disease onset; more commonly women; more likely to have limited disease and lower skin scores; less likely to have finger ulcers, digital tuft resorption, or finger contractures; more likely to have pulmonary hypertension; less likely to have interstitial lung disease, scleroderma renal crisis, inflammatory arthritis, and inflammatory myositis; and having lower overall disease severity. CENP-A and/or B status was predictive of the extent of skin involvement over time. Patients with limited disease who were CENP-A-negative at baseline were more likely to progress to diffuse disease compared to CENP-A-positive patients (OR 2.55, 95% CI 1.37, 4.85,  $p = 0.004$ ).

**Conclusion.** Clinical immunology laboratories are increasingly using high-throughput ELISA tests for CENP antibodies, with or without ACA detected by indirect immunofluorescence. The phenotype of CENP-A and/or B-positive patients is generally similar to that associated with ACA. (First Release March 1 2012; J Rheumatol 2012;39:787–94; doi:10.3899/rheum.111133)

## Key Indexing Terms:

SYSTEMIC SCLEROSIS  
CENP-A ANTIBODIES

AUTOANTIBODIES

ANTICENTROMERE ANTIBODIES  
CENP-B ANTIBODIES

Autoantibodies are seen in more than 95% of patients with systemic sclerosis (SSc)<sup>1</sup> and include several highly specific SSc-related autoantibodies, in particular anticentromere (ACA), topoisomerase I, and RNA polymerase III antibody<sup>1,2</sup>.

From the Division of Rheumatology, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada; Inova Diagnostics, Inc., San Diego, California, USA; Division of Rheumatology, Faculty of Medicine, University of Western Ontario, London, Ontario, Canada; and Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

Supported in part by the Canadian Institutes of Health Research, the Scleroderma Society of Canada and educational grants from Actelion Pharmaceuticals and Pfizer Inc. Autoantibody diagnostic kits were a gift of Inova Diagnostics Inc. (San Diego, CA, USA), ImmunoConcepts (Sacramento, CA, USA), and Dr. Fooko Laboratorien GmbH (Neuss, Germany). Dr. Hudson is a New Investigator supported by the Canadian Institutes of Health Research and the Fonds de la recherche en Santé du Québec, and Dr. Fritzler holds the Arthritis Society Research Chair at the University of Calgary.

M. Hudson, MD, MPH, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital; M. Mahler, PhD, Inova Diagnostics Inc.; J. Pope, MD, Division of Rheumatology, Faculty of Medicine, University of Western Ontario; D. You, Faculty of Medicine, University of Calgary; S. Tatibouet, MSc; R. Steele, PhD; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital; M. Fritzler, PhD, MD, Faculty of Medicine, University of Calgary.

Address correspondence to Dr. M. Hudson, Jewish General Hospital, Room A-725, 3755 Cote Ste Catherine Road, Montreal, Quebec H3T 1E2, Canada. E-mail: marie.hudson@mcgill.ca

Accepted for publication November 10, 2011.

ies<sup>1,2</sup>. Interestingly, expression of these autoantibodies tends to be mutually exclusive<sup>2,3</sup> and associated with specific demographic, clinical, genetic, and prognostic features<sup>2,4</sup>. Thus, SSc autoantibodies are highly valuable for the diagnosis and prognosis of the disease. In addition, growing knowledge of SSc autoantibodies is increasing understanding of the pathogenesis of the disease<sup>5,6,7</sup>.

ACA, one of the hallmark autoantibodies of SSc, has a sensitivity in the range of 20%–40% and specificity > 90%<sup>1,2</sup>. ACA are typically associated with limited cutaneous disease and/or CREST manifestations (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasias)<sup>4</sup>. ACA have been reported to antedate the full clinical expression of disease<sup>8</sup> and patients with ACA have also been reported to be at higher risk for pulmonary hypertension and lower risk of interstitial lung disease (ILD) and scleroderma renal crisis<sup>4,9,10,11</sup>.

In the clinical setting, ACA have traditionally been identified by indirect immunofluorescence (IIF), which identifies autoantibodies that bind to centromeric proteins (CENP), major constituents of the primary constriction of metaphase chromosomes. CENP autoantigens identified to date include CENP-A (17 kDa), CENP-B (80 kDa), CENP-C (140 kDa), CENP-D (50 kDa), CENP-E (312

kDa), CENP-F (400 kDa), CENP-G (95 kDa), and CENP-O (38 kDa)<sup>12</sup>. While this list continues to expand, most clinical attention has focused on CENP-A and CENP-B, which for the most part are the antigens detected by IIF in SSc and other sera<sup>13</sup>.

With the availability of commercially prepared and highly purified CENP, other immunoassays such as the ELISA, line immunoassay, and addressable laser bead immunoassays have been developed and are increasingly used in diagnostic laboratories. While a few studies have examined the prevalence of CENP-A and -B in SSc<sup>14,15</sup>, little has been published on the clinical correlates of the individual CENP-A or CENP-B autoantibodies. Because of the wider use of these CENP ELISA and limited clinical studies, we set out to study and identify the clinical phenotypes of CENP-A and B-positive patients with SSc and to compare them to ACA-positive and negative SSc patients. For clarity in this report, ACA will be used to refer to anticentromere antibodies detected by IIF on HEp-2 substrate.

## MATERIALS AND METHODS

**Study subjects.** The Canadian Scleroderma Research Group (CSRG) is a consortium of clinical and basic science researchers who follow a cohort of patients with SSc recruited from 15 centers across Canada. Patients in the registry must have a diagnosis of SSc confirmed by a rheumatologist, be > 18 years of age, and be fluent in either English or French. Patients have been recruited since 2004 and are seen at baseline and thereafter yearly. For this study, subjects with complete serological data for ACA as detected by IIF, CENP-A and CENP-B detected by ELISA, and anti-topoisomerase I and RNA polymerase III were included.

Patients recruited into the CSRG registry undergo an extensive standardized evaluation. Serum samples are collected at baseline and yearly according to a standardized operating protocol and shipped to the University of Calgary (Calgary, AB, Canada) where they are aliquoted and stored at -70°C until used. Ethics committee approval for the CSRG data collection and study protocols was obtained at McGill University (Montreal, QC, Canada) and at all participating study sites. All subjects provided informed written consent to participate.

**Autoantibody assays.** IIF was performed on HEp-2 substrate (HEp-2000; ImmunoConcepts, Sacramento, CA, USA) that included fluorescein-conjugated goat antibodies to human IgG (H+L) in Calgary (Mitogen Advanced Diagnostics). IIF patterns were detected at serum dilutions of 1:160 and 1:640 on a Zeiss Axioskop 2 plus (Carl Zeiss, Jena, Germany) fitted with a 100-watt Ushio super-high-pressure mercury lamp (Ushio, Steinhöring, Germany) by 2 experienced technologists, who had no knowledge of the CENP-A or CENP-B ELISA results.

CENP-B ELISA (Dr. Fooke Laboratorien GmbH, Neuss, Germany) with recombinant full-length CENP-B expressed in insect cells was performed according to the manufacturer's instructions. The CENP-A ELISA (Dr. Fooke Laboratorien GmbH), a CE-certified peptide-based assay, was performed according to the manufacturer's instructions as described<sup>14</sup>. The optical density of each well was read and recorded on a Biomek1000 (Beckman Instruments, Palo Alto, CA, USA).

Samples were also tested for topoisomerase I by Quanta Plex™ SLE8 (Inova Diagnostics Inc., San Diego, CA, USA) and RNA Pol III by Quanta Lite® RNA Pol III (Inova Diagnostics Inc.) as described<sup>16</sup>.

**Clinical assessments.** Extensive medical evaluation was done, with standardized collection of clinical, laboratory, and radiologic data. Demographic variables were self-reported by the patients. Disease duration was

recorded by the study physician and determined from the onset of the first non-Raynaud's disease manifestation. Skin involvement was assessed using the modified Rodnan skin score<sup>17</sup>, a widely used clinical assessment where the examining rheumatologist records the degree of skin thickening ranging from 0 (no involvement) to 3 (severe thickening) in 17 areas (total score range 0–51), and patients were classified into limited and diffuse cutaneous subsets, based on the definition of LeRoy, *et al*<sup>18</sup>. Study physicians recorded the presence of Raynaud's phenomenon, calcinosis, esophageal dysmotility, sclerodactyly, clinically visible mat-like telangiectasias on the face, limbs, chest or abdomen, active or healed fingertip ulcers, digital tuft resorption, and current medications. A history of scleroderma renal crisis, inflammatory polyarthritis, inflammatory myositis, malabsorption, and/or pseudoobstruction according to the study physician was also recorded. The presence of finger contractures was assessed with the fingertip-to-palm (FTP) distance recorded from the tip of the third finger to the distal palmar crease using the more severely affected hand. FTP distance has been recommended as a measure of finger contracture severity in SSc<sup>19</sup> and has been used in previous studies<sup>20,21,22</sup>.

To further assess gastrointestinal involvement, patients answered yes/no to a series of 14 questions concerning appetite loss, difficulty swallowing, regurgitation of acid, nocturnal choking, heartburn, early satiety, abdominal bloating, nausea and vomiting, constipation, diarrhea, need for antibiotics for diarrhea, greasy stools, fecal incontinence, and need for parenteral nutrition. Patients also reported the severity of their gastrointestinal symptoms on a numerical rating scale ranging from 0, representing no disease, to 10, representing very severe disease.

Cardiopulmonary involvement was determined by symptoms, physical examination, chest radiograph, high-resolution computed tomographic (HRCT) scans of the chest, pulmonary function tests, and cardiac echocardiography. New York Heart Association functional class I–IV and the presence of typical “Velcro-like crackles” indicative of ILD on lung auscultation was determined by the study physician. Chest radiographs were reviewed by radiologists and the presence of increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis was recorded. HRCT scans of the chest were also reviewed by radiologists and the presence of ground-glass, interstitial disease, or honeycombing was recorded. Pulmonary function testing was performed in laboratories working in accordance with American Thoracic Society standards. Data were extracted concerning forced vital capacity, total lung capacity, and carbon monoxide diffusing lung capacity using the single-breath method, and are expressed as a percentage of predicted. Pulmonary artery pressure (PAP) was measured by cardiologists using the Doppler flow measurement of the tricuspid regurgitant jet on echocardiography.

For the purposes of this study, ILD was considered present if a HRCT scan of the lungs showed ground-glass, interstitial disease, or honeycombing. In the case where no HRCT was available, ILD was considered present if either a chest radiograph was reported as showing either increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis, and/or if a study physician reported findings indicative of ILD on physical examination. Pulmonary hypertension was defined as an estimated systolic PAP > 45 mm Hg (an estimate that correlates strongly with right heart catheter studies<sup>23</sup>).

Finally, physicians and patients completed global assessments of disease severity, using an 11-point numerical rating scale ranging from 0, representing no disease, to 10, representing very severe disease.

**Statistical evaluation.** Descriptive statistics were used to summarize the baseline characteristics of the cohort and to compare ACA, CENP-A, and CENP-B-positive and negative patients. Receiver-operation characteristic (ROC) curves were used to determine the optimal cutoffs for the CENP-A and CENP-B assays to identify patients classified as having limited or diffuse cutaneous disease. Two-by-two tables were constructed to determine whether CENP-A and CENP-B-positive/negative status could predict limited/diffuse disease subsets. Positive and negative predictive values of CENP-A and CENP-B antibodies were examined at various antibody cutoffs. All statistical analyses were performed using SAS 9.2 (SAS Institute,

Chicago, IL, USA) and R: A Language and Environment for Statistical Computing, v.2.10.0 (R Foundation, Vienna, Austria; <http://www.R-project.org>).

## RESULTS

Our study included 802 patients with SSc with complete serological profiles. The mean age ( $\pm$  SD) was 56 ( $\pm$  12)

years, 86% were women, 85% were white, mean disease duration was 11 ( $\pm$  9) years, and 38% had diffuse disease (Table 1). ACA detected by IIF on HEp-2 substrate were identified in 279 patients (35%). In addition, topoisomerase I antibodies were identified in 128 (16%) and RNA polymerase III antibodies in 144 patients (19%).

Table 1. Baseline characteristics of the study cohort as a whole and for those positive for ACA\*, CENP-A, and CENP-B.

| Characteristic  | Whole Group,<br>n = 802 |         | ACA,<br>n = 279 |         | CENP-A,<br>n = 276 |         | CENP-B,<br>n = 286 |         | Other (not ACA, CENP-A,<br>CENP-B), n = 501 |         |
|---|-------------------------|---------|-----------------|---------|--------------------|---------|--------------------|---------|---|---------|
|   | Mean or<br>N            | SD or % | Mean or<br>N    | SD or % | Mean or<br>N       | SD or % | Mean or<br>N       | SD or % | Mean or<br>N                                | SD or % |
| Mean age, yrs   | 55.78                   | 12.20   | 59.70           | 11.31   | 59.00              | 11.53   | 59.58              | 11.39   | 53.85                                       | 12.06   |
| Female, %   | 688                     | 85.79   | 263             | 94.27   | 257                | 93.12   | 266                | 93.01   | 409   | 81.64   |
| White, %  | 683                     | 85.16   | 244             | 87.46   | 239                | 86.59   | 249                | 87.06   | 424   | 84.63   |
| Aboriginal, %   | 39                      | 4.86    | 13              | 4.66    | 14                 | 5.07    | 14                 | 4.90    | 23  | 4.59    |
| Disease duration, yrs   | 10.83                   | 9.18    | 11.98           | 9.16    | 11.81              | 9.19    | 11.93              | 9.40    | 10.19                                       | 9.03    |
| Age at disease onset, yrs                                     | 44.91                   | 13.64   | 47.75           | 13.56   | 47.20              | 13.65   | 47.68              | 13.72   | 43.54                                       | 13.36   |
| Disease subsets, %  |                         |         |                 |         |                    |         |                    |         |   |         |
| Limited disease   | 461                     | 58.43   | 223             | 81.68   | 218                | 80.74   | 228                | 81.14   | 226   | 45.75   |
| Diffuse disease   | 303                     | 38.40   | 38              | 13.92   | 41                 | 15.19   | 41                 | 14.59   | 255   | 51.62   |
| Sine scleroderma  | 25                      | 3.17    | 12              | 4.40    | 11                 | 4.07    | 12                 | 4.27    | 13  | 2.63    |
| Modified Rodnan skin score                                    | 10.16                   | 9.49    | 6.52            | 6.13    | 6.70               | 6.34    | 6.62               | 6.36    | 12.15                                       | 10.41   |
| Calcinosis, %   | 247                     | 30.95   | 91              | 32.62   | 88                 | 31.88   | 94                 | 32.87   | 148   | 29.78   |
| Raynaud's, %  | 777                     | 97.49   | 275             | 98.92   | 271                | 98.55   | 283                | 98.95   | 481   | 96.78   |
| Esophageal dysmotility, %                                     | 503                     | 69.86   | 194             | 75.19   | 192                | 74.42   | 197                | 74.34   | 295   | 66.89   |
| Sclerodactyly, %  | 736                     | 92.81   | 251             | 91.27   | 249                | 91.54   | 258                | 97.17   | 464   | 93.55   |
| Telangiectasias, %  | 580                     | 76.52   | 221             | 81.85   | 213                | 79.78   | 226                | 81.59   | 348   | 74.68   |
| Fingertip ulcers, %   | 451                     | 56.73   | 145             | 52.35   | 142                | 51.82   | 148                | 51.93   | 292   | 58.87   |
| No. fingertip ulcers  | 1.18                    | 2.41    | 0.83            | 1.66    | 0.86               | 1.70    | 0.84               | 1.65    | 1.36  | 2.74    |
| Digital tuft resorption, %                                    | 327                     | 41.60   | 90              | 32.97   | 91                 | 33.70   | 94                 | 33.45   | 226   | 46.03   |
| Finger contractures, %  | 213                     | 29.06   | 40              | 15.87   | 39                 | 15.60   | 44                 | 16.86   | 166   | 36.17   |
| Inflammatory polyarthritis, %                                 | 246                     | 32.11   | 63              | 23.86   | 65                 | 24.71   | 66                 | 24.26   | 173   | 36.04   |
| No. GI symptoms (range 0–14)                                  | 4.16                    | 3.13    | 4.48            | 3.23    | 4.49               | 3.28    | 4.49               | 3.20    | 3.96  | 3.05    |
| Malabsorption, %  | 123                     | 15.51   | 39              | 14.13   | 39                 | 14.29   | 37                 | 13.03   | 82  | 16.57   |
| Pseudoobstruction, %  | 32                      | 4.05    | 17              | 6.16    | 16                 | 5.86    | 17                 | 5.99    | 15  | 3.05    |
| Severity of GI symptoms<br>(range 0–10)                       | 1.78                    | 2.61    | 1.82            | 2.69    | 1.83               | 2.73    | 1.83               | 2.70    | 1.74  | 2.55    |
| NYHA class  |                         |         |                 |         |                    |         |                    |         |   |         |
| I   | 391                     | 49.49   | 146             | 52.71   | 148                | 54.01   | 152                | 53.33   | 232   | 47.25   |
| II  | 322                     | 40.76   | 108             | 38.99   | 102                | 37.23   | 108                | 37.89   | 208   | 42.36   |
| III   | 61                      | 7.72    | 16              | 5.78    | 17                 | 6.20    | 18                 | 6.32    | 42  | 8.55    |
| IV  | 16                      | 2.03    | 7               | 2.53    | 7                  | 2.55    | 7                  | 2.46    | 9   | 1.83    |
| Pulmonary hypertension, %                                     | 82                      | 12.18   | 38              | 15.97   | 38                 | 16.38   | 39                 | 16.12   | 43  | 10.26   |
| Currently on PAH drugs, %                                     | 32                      | 4.03    | 14              | 5.04    | 14                 | 5.09    | 13                 | 4.58    | 18  | 3.63    |
| Interstitial lung disease, %                                  | 291                     | 36.98   | 59              | 21.53   | 56                 | 20.66   | 61                 | 21.63   | 223   | 45.42   |
| FVC, % predicted  | 90.89                   | 19.51   | 97.20           | 19.02   | 97.21              | 18.94   | 97.26              | 19.13   | 87.37                                       | 19.01   |
| DLCO, % predicted   | 71.60                   | 21.56   | 71.66           | 19.71   | 72.46              | 19.84   | 72.11              | 19.51   | 71.28                                       | 22.61   |
| Proportion with FVC/DLCO<br>> 1.6, %                          | 156                     | 23.89   | 71              | 30.47   | 68                 | 29.57   | 70                 | 29.29   | 83  | 20.65   |
| Scleroderma renal crisis, %                                   | 39                      | 4.95    | 0               | 0.00    | 0                  | 0.00    | 1                  | 0.35    | 38  | 7.74    |
| Abnormal creatinine in the<br>absence of SRC, %               | 148                     | 20.56   | 81              | 30.80   | 79                 | 30.38   | 84                 | 31.11   | 64  | 14.65   |
| Inflammatory myositis, %                                      | 84                      | 11.20   | 12              | 4.56    | 13                 | 4.96    | 15                 | 5.54    | 67  | 14.38   |
| Mean physician global assessments<br>of severity (range 0–10) | 2.75                    | 2.25    | 2.26            | 2.09    | 2.26               | 2.11    | 2.29               | 2.11    | 3.01  | 2.29    |
| Mean patient global assessments of<br>severity (range 0–10)   | 3.69                    | 2.60    | 3.39            | 2.62    | 3.33               | 2.63    | 3.41               | 2.64    | 3.85  | 2.57    |

\* ACA refers to anticentromere antibodies as detected by IIF on HEp-2 substrate. CENP: centromeric proteins; FVC: forced vital capacity; GI: gastrointestinal; NYHA: New York Heart Association; PAH: pulmonary arterial hypertension; SRC: scleroderma renal crisis; IIF: indirect immunofluorescence.

**Cutoffs for CENP-A and CENP-B.** When the ELISA cutoff values of 1.5 calculated units (CU) recommended by the manufacturers were used initially, the clinical associations (e.g., disease phenotypes) of CENP-A and CENP-B antibodies were less distinct than those of ACA as detected by IIF. Therefore, we first undertook to determine the optimal cutoffs for “positive” values for CENP-A and CENP-B. To do this, we made the assumption that, as for ACA by IIF, both CENP-A and CENP-B would be associated with limited cutaneous disease. Using ROC curves and maximizing the weighted averages of the sensitivities and specificities for the respective antibody, we found that the optimal cutoff for CENP-A was 3.58 CU and for CENP-B 2.17 CU (Figure 1). Using these cutoffs, ELISA-based assays detected CENP-A antibodies in 276 (34%) sera and CENP-B antibodies in 286 (36%) sera. For CENP-A, the optimized cut-off yielded a sensitivity of 47% and a specificity of 88%, compared to a sensitivity of 49% and a specificity of 87% for CENP-B, for the detection of limited versus diffuse cutaneous disease. The area under the curve (AUC) was 0.677 for CENP-A and 0.671 for CENP-B. Note that an AUC of 0.7 is generally regarded as “reasonable” and our results are slightly below that, likely because of relatively higher specificity (low number of diffuse patients who are classified as positive) but lower sensitivity (high number of limited patients who were not positive).

**Similarities among CENP-A, CENP-B, and ACA-positive patients.** As expected, using the cutoffs for CENP-A and CENP-B described above, there was considerable overlap among ACA, CENP-A, and CENP-B-positive patients (Figure 2). Of the 301 patients positive for any 1 of those 3 antibodies, 260 (86%) were positive for all 3. ACA identified 279 patients (92%), CENP-A identified 276 patients (92%), and CENP-B identified 286 patients (95%). The overlap among topoisomerase I and ACA, CENP-A, and CENP-B was low, in the order of 1% (Figure 3A). This was also the case for the overlap of RNA polymerase III and ACA, CENP-A, and CENP-B (Figure 3B).

When we compared their characteristics, the overall characteristics of ACA, CENP-A, and CENP-B-positive patients were very similar to each other but different from the remainder of the CSRG cohort (Table 1). Among other things, ACA, CENP-A, and/or CENP-B patients resembled each other and differed from the remainder of the cohort in the following respects: older chronologically and at disease onset; more commonly women; more likely to have limited disease and lower skin scores; less likely to have finger ulcers, digital tuft resorption, or finger contractures; more likely to have pulmonary hypertension; less likely to have ILD, scleroderma renal crisis, inflammatory arthritis, and inflammatory myositis; and lower overall disease severity. Note that it is not meaningful to compare the various groups




Figure 1. Receiver-operation characteristic (ROC) curves for CENP-A and CENP-B to identify SSc patients with either limited or diffuse skin involvement.






Figure 2. The overlap of anticentromere antibodies (ACA), CENP-A, and CENP-B-positive patients.

using p values because the groups are not mutually exclusive (i.e., there are many patients who are positive for ACA, CENP-A, and CENP-B). Thus, these results should be interpreted by looking at whether the groups are similar or different in clinically meaningful ways.

**Positive and negative predictive values of CENP-A and B.** An alternative way to think about the characteristics of CENP-A and B is to consider their positive (PPV) and negative (NPV) predictive values, which was the proportion of CENP-A (or CENP-B) positive patients who are limited and the proportion of CENP-A (or CENP-B) negative patients who are diffuse. We examined the PPV and NPV of CENP-A and CENP-B over the range of possible cutoffs for those assays (Figure 4); interestingly, the PPV was much higher than the NPV. In other words, the proportion of CENP-positive patients who are limited was quite high (over 85%). However, the NPV was much lower. Thus, again, CENP positivity was predictive of the limited cutaneous phenotype, whereas negativity was associated with much greater uncertainty about whether the patients had either limited or diffuse disease. It is worthwhile to note that PPV and NPV were also maximized at cutoffs similar to those identified by the ROC curves described above.

**Predictive ability of CENP-A and B.** To illustrate that the CENP-A and CENP-B phenotypes are similar to ACA, we considered that ACA positivity is usually predictive of limited skin involvement. We wished to determine whether CENP positivity was also predictive of the extent of skin involvement over time. We therefore looked at patients who were identified as having limited skin disease at baseline




Figure 3. The overlap of anticentromere antibodies (ACA), CENP-A, CENP-B, and (A) topoisomerase I (topo I) and (B) RNA polymerase III (RNA pol III)-positive patients.

and then examined their limited/diffuse status over time. We included only patients who had 4 or more yearly visits (i.e., 3 after baseline). There were 209 limited patients at baseline with at least 3 visits after baseline. Limited patients who were CENP-A-negative at baseline were more than twice as likely to progress to diffuse disease compared to patients who were CENP-A-positive (OR 2.55, 95% CI 1.37, 4.85;  $p = 0.004$ ; Table 2). The results were similar for CENP-B (data not shown). Thus, CENP-A and/or B status was predictive of the extent of skin involvement over time.

## DISCUSSION

In this large cohort of Canadian patients with SSc with well-defined clinical phenotypes, ACA, CENP-A, and CENP-B antibodies identified virtually all of the same




Figure 4. Positive (PPV) and negative (NPV) predictive values of CENP-A and CENP-B to identify patients with limited or diffuse skin involvement at various assay cutoff values. Vertical lines represent the “optimal” cutoffs for CENP-A (solid line) and CENP-B (broken line).

Table 2. Association between CENP-A positive and negative status and limited and diffuse skin involvement during followup in patients with limited skin disease at baseline and at least 3 years of followup (n = 209).

| Status          | Limited Disease Patients Who Remained Limited Over Followup (%) | Limited Disease Patients Who Became Diffuse Over Followup (%) |
|-----------------|---|---|
| CENP-A positive | 85 (81)   | 20 (19)   |
| CENP-A negative | 65 (62)   | 39 (38)   |

CENP: centromeric proteins.

patients. Not surprisingly, then, the clinical correlates of ACA-positive antibodies were highly similar to those of CENP-A and CENP-B-positive antibodies. This information is of considerable clinical importance because clinical immunology laboratories are increasingly using high-throughput ELISA tests for CENP antibodies, with or without ACA detected by IIF. Accordingly, it is imperative that clinicians should be informed that the phenotype that they generally associate with ACA in SSc is similar to that which they should associate with CENP-A and/or B-positive antibodies.

Two previous studies examined the clinical associations of CENP-A and B antibodies in SSc. Mahler, *et al*<sup>14</sup> evaluated the sensitivity and specificity of the CENP-A in 90 SSc sera samples using the same ELISA kit used in our study and showed that it was a sensitive and specific marker for SSc. Indeed, because ACA are occasionally found in other

autoimmune diseases such as systemic lupus erythematosus, it was suggested that the CENP-A assay was more specific for SSc. Moreover, consistent with our findings, their preliminary analysis of clinical correlates of the 90 patients with SSc showed that, overall, CENP-A-positive patients had lower modified Rodnan skin scores than CENP-A-negative patients. Hanke, *et al*<sup>15</sup> recently published a study examining the clinical correlates of CENP-A and CENP-B antibodies, albeit measured with a different assay (Euroimmun), in 280 patients. They showed good sensitivity (37%) and high concordance (94%) of their CENP-A/CENP-B assays in patients with SSc. Also, consistent with our findings, antibodies to both CENP-A and B were associated with similar clinical manifestations and identified patients with limited disease phenotypes.

Interestingly, consistent with the findings reported by

Hanke, *et al*<sup>15</sup>, we found that ACA, CENP-A, and CENP-B overlapped considerably with each other. However, in SSc in general, and in our cohort in particular, autoantibodies to CENP, topoisomerase I, and RNA polymerase tended to be mutually exclusive<sup>2,3</sup>. This supports the notion that endogenous macromolecular complexes (e.g., centromeric chromatin) rather than molecular mimicry of exogenous antigens are what drive the B cell response in SSc<sup>24,25</sup>. However, CENP-A and CENP-B antibodies, although distinct proteins<sup>14</sup>, share a cross-reactive epitope motif that has been shown to mediate epitope spreading. It is possible that, for this reason, most SSc patients with 1 antibody may have antibodies to both centromere antigens<sup>26,27</sup>. Of note, unlike topoisomerase I and certain other nuclear antigens, CENP are not cleaved during Fas-mediated apoptosis<sup>28</sup>, suggesting that the antigens involved may induce B cell reactivity by other pathways.

In a longitudinal study of a patient with SSc<sup>26</sup>, it was shown that anti-CENP-A reactivity could be induced by intra- and intermolecular epitope spreading from histone H3 and that antibodies to CENP-A peptides could temporally precede autoreactivity to recombinant CENP-B. The CENP-A peptide ELISA used in this study was based on the same peptide epitope as the ELISA used in our study. In that context it is of high interest that patients who reacted with CENP-A but not CENP-B had significantly shorter disease duration than patients positive for CENP-B alone.

In this study, the prevalences of ACA, CENP-A, and CENP-B were almost identical (35%, 34%, and 36%, respectively). The prevalence of CENP-A and/or CENP-B increased to 37%. This suggests that an ELISA for CENP-A and/or CENP-B could possibly replace IIF for ACA. This is especially important given the greater resources and expertise required for IIF, compared to ELISA testing.

In the absence of a “gold standard,” choosing normal cutoffs for a test can be challenging. One approach is to set an arbitrary cutoff based on the distributional properties of the test (e.g., simply taking 2 SD from the general population mean). Another, more objective approach, is to use ROC curves to optimally classify patients according to an independent clinical characteristic. In our study, after optimizing the cutoffs for CENP-A and B based on their ability to differentiate between limited and diffuse cutaneous disease, we found that the clinical profiles of ACA, CENP-A, and CENP-B-positive patients were all very similar. There is circularity in this reasoning and to an extent the results are as expected. Nevertheless, by increasing the predictive ability of the test, ROC curve analysis enables identification of a “best cutoff” for clinical purposes.

SSc is characterized by a wide spectrum of clinical phenotypes and most attempts to create subsets of this disease to date, including the limited and diffuse subsets used in our study, rely on the extent of cutaneous involvement<sup>29</sup>. On the other hand, our data clearly show that about 20% of patients

with the limited phenotype are negative for ACA, CENP-A, and/or CENP-B, and that 15% of patients with diffuse disease are positive for 1 or more of those antibodies. Thus, understanding of the relationship between limited cutaneous disease and ACA is far from perfect. With this in mind, some investigators have advocated basing the subsets of the disease on antibody profiles, rather than clinical phenotypes<sup>10,30</sup>. Among other things, this may influence how we manage and follow patients clinically, improve our prognostic abilities, and direct genetic and basic science research, as well as serving as useful criteria for inclusion in clinical trials.

Our study contributes significantly to knowledge concerning the clinical significance of CENP-A and B in SSc. This is the largest and most detailed published analysis of the clinical correlates of CENP-A and B in SSc. The clinical phenotypes of CENP-A and/or B patients are generally consistent with that associated with ACA-positive patients. The data from this and previous studies<sup>14,15</sup> indicate that CENP-A and CENP-B assays can be used (1) to identify patients with SSc with high sensitivity and specificity; and (2) to identify the same clinical phenotypes as are known for ACA, using optimized cutoff values. Finally, many laboratories are moving to ELISA and other assays to screen and test for specific autoantibodies. Thus, it is important to appreciate that the clinical correlations of high-throughput assays, such as ELISA, are consistent with the time-honored ACA IIF assay.

## APPENDIX

*List of study collaborators.* Investigators of the Canadian Scleroderma Research Group: J. Markland, Saskatoon, Saskatchewan; D. Robinson, Winnipeg, Manitoba; N. Jones, Edmonton, Alberta; N. Khalidi, Hamilton, Ontario; P. Docherty, Moncton, New Brunswick; E. Kaminska, Hamilton, Ontario; A. Masetto, Sherbrooke, Quebec; E. Sutton, Halifax, Nova Scotia; J-P. Mathieu, Montreal, Quebec; S. Ligier, Montreal, Quebec; T. Grodzicky, Montreal, Quebec; C. Thorne, Newmarket, Ontario; S. LeClercq, Calgary, Alberta.

## REFERENCES

1. Steen VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum* 2005;35:35-42.
2. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies. *Arthritis Rheum* 2003;49:399-412.
3. Dick T, Mierau R, Bartz-Bazzanella P, Alavi M, Stoyanova-Scholz M, Kindler J, et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. *Ann Rheum Dis* 2002;61:121-7.
4. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. *Curr Opin Rheumatol* 2007;19:580-91.
5. Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. *Arthritis Rheum* 2009;60:2805-16.
6. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I

- autoantibodies from systemic sclerosis patients. *Arthritis Rheum* 2006;54:963-73.
7. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. *Arthritis Rheum* 2004;50:3265-74.
  8. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum* 2008;58:3902-12.
  9. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. *Rheumatology* 2009;48 Suppl 3:iii32-5.
  10. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research Group database. *Ann Rheum Dis* 2007;66:754-63.
  11. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. *Arthritis Res Ther* 2003;5:80-93.
  12. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. *Autoimmun Rev* 2011;10:194-200.
  13. Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. *Ann NY Acad Sci* 2010;1183: 267-87.
  14. Mahler M, Maes L, Blockmans D, Westhovens R, Bossuyt X, Riemekasten G, et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. *Arthritis Res Ther* 2010;12:R99.
  15. Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, et al. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. *J Rheumatol* 2010;37:2548-52.
  16. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. *J Rheumatol* 2007;34:1528-34.
  17. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. *J Rheumatol* 1995;22:1281-5.
  18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. *J Rheumatol* 1988; 15:202-5.
  19. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: Development and testing. *J Rheumatol* 1999;26:2159-67.
  20. Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, et al. Clinical features of scleroderma patients with contracture of phalanges. *Clin Rheumatol* 2007;26:1275-7.
  21. Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). *Ann Rheum Dis* 1982;41:147-52.
  22. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. *Best Pract Res Clin Rheumatol* 2008;22:339-50.
  23. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: Comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol* 2008;35:458-65.
  24. Craft JE, Hardin JA. Linked sets of antinuclear antibodies: what do they mean? *J Rheumatol Suppl.* 1987 Jun;14:106-9.
  25. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. *Immunol Today* 1995;16:90-8.
  26. Mahler M, Mierau R, Genth E, Bluthner M. Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. *Arthritis Rheum* 2002;46:1866-72.
  27. Mahler M, Mierau R, Bluthner M. Fine-specificity of the anti-CENP-A B-cell autoimmune response. *J Mol Med* 2000;78:460-7.
  28. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. *J Exp Med* 1996;184:765-70.
  29. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. *J Rheumatol* 2007;34:1855-63.
  30. Steen VD. The many faces of scleroderma. *Rheum Dis Clin North Am* 2008;34:1-15;v.